the preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets , liabilities , revenue , costs and expenses , and related disclosures . we evaluate our estimates and assumptions on an ongoing basis . our actual results may differ from these estimates . we believe that our significant accounting policies , which are described in note 2 to our consolidated financial statements , involve a degree of judgment and complexity . accordingly , we believe that the specific accounting policies described below are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of operations . revenue recognition we recognize revenue in accordance with accounting standards on revenue recognition . our principal sources of revenue are government research grants and research and development payments that are primarily derived from collaborative agreements with other companies . we recognize government grants as revenue because the grants are central to the company 's ongoing crop science program . revenue is earned as research expenses related to the grants are incurred . revenue earned on government grants , but not yet invoiced as of the balance sheet date , are recorded as unbilled receivables in the accompanying consolidated balance sheets for the years ended december 31 , 2016 and december 31 , 2015. funds received from government grants in advance of work being performed are recorded as deferred revenue until earned . stock-based compensation the accounting standards for stock-based compensation require that all stock-based awards to employees be recognized as an expense in the consolidated financial statements and that such expense be measured based on the fair value of the award . determining the appropriate fair value model and calculating the fair value of stock-based payment awards requires the use of highly subjective assumptions , including the expected life of the stock-based payment awards and stock price volatility . we use the black-scholes option-pricing model to value our service-based option grants and determine the related compensation expense . when we issue restricted stock units containing market and performance vesting conditions , we estimate the fair value and derived service period of these awards using a monte carlo valuation model . generally , we recognize the fair value of stock awards evenly over their vesting periods provided the employee , director or non-employee receiving the award continues to meet continuing service conditions . the assumptions used in calculating the fair value of stock-based awards represent management 's best estimates , but the estimates involve inherent uncertainties and the application of management judgment . see note 10 to the consolidated financial statements for further discussion on the key assumptions used to determine the fair values of option grants pursuant to the black-scholes option pricing model . discontinued operations a discontinued operation is a component of an entity that has either been disposed of , or that is classified as held for sale , which represents a separate major line of business or geographical area of operations and is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations . in accordance with the accounting guidance regarding the presentation of discontinued operations , the activity of our biopolymers component has been reclassified as a discontinued operation for the years ended december 31 , 2016 and 2015. in july 2016 , the company announced a strategic restructuring plan in which yield10 bioscience became its core business which resulted in the sale of its biopolymer operations in september 2016. results of operations the consolidated financial statements for the two years ending december 31 , 2016 , have been presented to reflect the former biopolymer operations of yield10 bioscience as a discontinued operation . 33 comparison of the years ended december 31 , 2016 and 2015 revenue replace_table_token_2_th total revenue from continuing operations was $ 1,159 and $ 1,350 for the years ended december 31 , 2016 and 2015 , respectively , and was derived solely from our research grants . the $ 191 decrease in grant revenue for the year ended december 31 , 2016 , is primarily the result of the refabb grant that ended in february 2016. during the year ended december 31 , 2016 , we did not recognize any further revenue from the refabb grant . during the year ended december 31 , 2015 , $ 1,028 was recognized from this grant . no revenue was recognized from the refabb grant during 2016. partially offsetting this decrease were increased grant revenues of $ 1,126 recognized from our two camelina grants . we anticipate that grant revenue will increase over the next twelve months as we continue to make progress on our current outstanding grants while seeking to obtain and apply resources to additional government grants during 2017. expenses replace_table_token_3_th research and development expenses research and development expenses from continuing operations were $ 5,670 and $ 6,602 for the years ended december 31 , 2016 and 2015 , respectively . the decrease of $ 932 was primarily due to a decrease in employee compensation and related benefit expenses . employee compensation and related benefit expenses were $ 2,624 and $ 3,247 for the years ended december 31 , 2016 and 2015 , respectively . the decrease of $ 623 is primarily attributable to decreases in headcount and the elimination of the 2016 bonuses as a result of our strategic restructuring and ongoing efforts to conserve cash . research facility expenses also decreased by $ 586 from $ 2,421 during the year ended december 31 , 2015 to $ 1,835 for the year ended december 31 , 2016 , primarily as a result of the company 's move to its new woburn , massachusetts facility . story_separator_special_tag restricted cash consists of $ 307 held in connection with the lease agreement for our woburn , massachusetts facility and $ 125 held in connection with our corporate credit card program . 35 investments are made in accordance with our corporate investment policy , as approved by our board of directors . the primary objective of this policy is to preserve principal and investments are limited to high quality corporate debt , u.s. treasury bills and notes , money market funds , bank debt obligations , municipal debt obligations and asset-backed securities . the policy establishes maturity limits , concentration limits , and liquidity requirements . as of december 31 , 2016 , we were in compliance with this policy . we anticipate that our current cash resources will be sufficient to fund operations and meet our obligations , including our restructuring obligations , when due , into the fourth quarter of 2017. this forecast of cash resources is forward-looking information that involves risks and uncertainties , and the actual amount of expenses could vary materially and adversely as a result of a number of factors . we have adopted the new guidance of asu 2014-15 , presentation of financial statements-going concern ( subtopic 205-40 ) in order to determine whether there is substantial doubt about the company 's ability to continue as a going concern for one year after the date its financial statements are issued . the company 's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through , among other sources , public or private equity financing , secured or unsecured debt financing , equity or debt bridge financing , additional government research grants or collaborative arrangements with third parties , as to which no assurances can be given . we do not know whether additional financing will be available on terms favorable or acceptable to the company when needed , if at all . if adequate additional funds are not available when required , or if we are unsuccessful in entering collaborative arrangements for further research , we may be forced to curtail our research efforts , explore strategic alternatives and or wind down our operations and pursue options for liquidating our remaining assets , including intellectual property and equipment . based on our cash forecast , we have determined that the company 's present capital resources are not sufficient to fund our planned operations for a twelve month period , and therefore , raise substantial doubt about its ability to continue as a going concern . although we have $ 20,000 of availability under our equity facility with aspire , market conditions likely will limit the extent to which the company can draw on this facility . we continue to face significant challenges and uncertainties and , as a result , our available capital resources may be consumed more rapidly than currently expected due to ( a ) changes we may make to the business that affect ongoing operating expenses ; ( b ) changes we may make to our business strategy ; ( c ) changes in our research and development spending plans ; and ( d ) other items affecting our forecasted level of expenditures and use of cash resources . our present capital resources will not be sufficient to fund our planned operations for a twelve month period , and therefore , raise substantial doubt about our ability to continue as a going concern . during 2016 , we completed a strategic restructuring of our operations to focus on the yield10 bioscience business . we reduce staffing levels to twenty full-time employees and incurred restructuring costs for contract termination and employee post-termination benefits of approximately $ 3,525 which are primarily reflected in discontinued operations within the company 's statement of operations . at december 31 , 2016 , $ 2,048 of these restructuring charges remain outstanding and are required to be paid out through may 2018. we currently anticipate that we will use approximately $ 7,500 - $ 8,000 of cash during 2017 , including anticipated payments for restructuring costs . this estimated cash usage for operations is significantly less than cash used for operations of $ 14,700 and $ 21,863 during the years ended december 31 , 2016 and 2015 , respectively , and the reduction is primarily the result of our restructuring efforts . on october 7 , 2015 , we entered into a common stock purchase agreement with aspire under which aspire is committed to purchase , at our direction , up to an aggregate of $ 20,000 of shares of our common stock over a 30 month period that will end on may 8 , 2018. common stock may be sold from time to time at the company 's option under pricing formulas based on prevailing market prices around the time of each sale . the extent to which we utilize the facility with aspire as a source of funding will depend on a number of factors , including the prevailing market price of our common stock , the volume of trading in our common stock and the extent to which we are able to secure funds from other sources . the purchase agreement contains limitations on the number of shares that we may issue to aspire . additionally , we and aspire may not effect any sales of shares of our common stock under the purchase agreement during the continuance of an event of default or on any trading day that the closing sale price of our common stock is less than $ 0.50 per share . at december 31 , 2016 , the market price for the company 's common stock was below $ 0.50 and the full $ 20,000 remained available under the purchase agreement with aspire . on december 30 , 2016 , the market price for our common stock closed at $ 0.35 per share . we will need additional capital to

net cash used for operating activities was $ 14,700 during the year ended december 31 , 2016 , compared to net cash used by operating activities during 2015 of $ 21,863 . net cash used by operations during the year ended december 31 , 2016 , primarily reflects the net loss of $ 7,604 , the add-back of the gain on the sale of the company 's discontinued biopolymer assets , including certain property and equipment , totaling $ 9,833 that is shown within cash proceeds under investing activities , the payment of 2015 performance bonuses during early 2016 of $ 1,665 , partially offset by non-cash expenses , including stock-based compensation expense of $ 848 , depreciation expense of $ 515 , inventory impairment write-downs totaling $ 199 , the company 's 401 ( k ) stock matching contribution expense of $ 281 and the settlement of certain restructuring costs through transfers of manufacturing equipment and the issuance of yield10 bioscience common stock . the following are the non-cash operating items and investing items related to discontinued operations for the years ended december 31 , 2016 and december 31 , 2015. replace_table_token_5_th net cash of $ 9,752 was provided by investing activities during the year ended december 31 , 2016 , compared tonet cash used by investing activities during 2015 of $ 614 .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```net cash used for operating activities was $ 14,700 during the year ended december 31 , 2016 , compared to net cash used by operating activities during 2015 of $ 21,863 . net cash used by operations during the year ended december 31 , 2016 , primarily reflects the net loss of $ 7,604 , the add-back of the gain on the sale of the company 's discontinued biopolymer assets , including certain property and equipment , totaling $ 9,833 that is shown within cash proceeds under investing activities , the payment of 2015 performance bonuses during early 2016 of $ 1,665 , partially offset by non-cash expenses , including stock-based compensation expense of $ 848 , depreciation expense of $ 515 , inventory impairment write-downs totaling $ 199 , the company 's 401 ( k ) stock matching contribution expense of $ 281 and the settlement of certain restructuring costs through transfers of manufacturing equipment and the issuance of yield10 bioscience common stock . the following are the non-cash operating items and investing items related to discontinued operations for the years ended december 31 , 2016 and december 31 , 2015. replace_table_token_5_th net cash of $ 9,752 was provided by investing activities during the year ended december 31 , 2016 , compared tonet cash used by investing activities during 2015 of $ 614 .
```    
 Suspicious Activity Report : the preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets , liabilities , revenue , costs and expenses , and related disclosures . we evaluate our estimates and assumptions on an ongoing basis . our actual results may differ from these estimates . we believe that our significant accounting policies , which are described in note 2 to our consolidated financial statements , involve a degree of judgment and complexity . accordingly , we believe that the specific accounting policies described below are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of operations . revenue recognition we recognize revenue in accordance with accounting standards on revenue recognition . our principal sources of revenue are government research grants and research and development payments that are primarily derived from collaborative agreements with other companies . we recognize government grants as revenue because the grants are central to the company 's ongoing crop science program . revenue is earned as research expenses related to the grants are incurred . revenue earned on government grants , but not yet invoiced as of the balance sheet date , are recorded as unbilled receivables in the accompanying consolidated balance sheets for the years ended december 31 , 2016 and december 31 , 2015. funds received from government grants in advance of work being performed are recorded as deferred revenue until earned . stock-based compensation the accounting standards for stock-based compensation require that all stock-based awards to employees be recognized as an expense in the consolidated financial statements and that such expense be measured based on the fair value of the award . determining the appropriate fair value model and calculating the fair value of stock-based payment awards requires the use of highly subjective assumptions , including the expected life of the stock-based payment awards and stock price volatility . we use the black-scholes option-pricing model to value our service-based option grants and determine the related compensation expense . when we issue restricted stock units containing market and performance vesting conditions , we estimate the fair value and derived service period of these awards using a monte carlo valuation model . generally , we recognize the fair value of stock awards evenly over their vesting periods provided the employee , director or non-employee receiving the award continues to meet continuing service conditions . the assumptions used in calculating the fair value of stock-based awards represent management 's best estimates , but the estimates involve inherent uncertainties and the application of management judgment . see note 10 to the consolidated financial statements for further discussion on the key assumptions used to determine the fair values of option grants pursuant to the black-scholes option pricing model . discontinued operations a discontinued operation is a component of an entity that has either been disposed of , or that is classified as held for sale , which represents a separate major line of business or geographical area of operations and is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations . in accordance with the accounting guidance regarding the presentation of discontinued operations , the activity of our biopolymers component has been reclassified as a discontinued operation for the years ended december 31 , 2016 and 2015. in july 2016 , the company announced a strategic restructuring plan in which yield10 bioscience became its core business which resulted in the sale of its biopolymer operations in september 2016. results of operations the consolidated financial statements for the two years ending december 31 , 2016 , have been presented to reflect the former biopolymer operations of yield10 bioscience as a discontinued operation . 33 comparison of the years ended december 31 , 2016 and 2015 revenue replace_table_token_2_th total revenue from continuing operations was $ 1,159 and $ 1,350 for the years ended december 31 , 2016 and 2015 , respectively , and was derived solely from our research grants . the $ 191 decrease in grant revenue for the year ended december 31 , 2016 , is primarily the result of the refabb grant that ended in february 2016. during the year ended december 31 , 2016 , we did not recognize any further revenue from the refabb grant . during the year ended december 31 , 2015 , $ 1,028 was recognized from this grant . no revenue was recognized from the refabb grant during 2016. partially offsetting this decrease were increased grant revenues of $ 1,126 recognized from our two camelina grants . we anticipate that grant revenue will increase over the next twelve months as we continue to make progress on our current outstanding grants while seeking to obtain and apply resources to additional government grants during 2017. expenses replace_table_token_3_th research and development expenses research and development expenses from continuing operations were $ 5,670 and $ 6,602 for the years ended december 31 , 2016 and 2015 , respectively . the decrease of $ 932 was primarily due to a decrease in employee compensation and related benefit expenses . employee compensation and related benefit expenses were $ 2,624 and $ 3,247 for the years ended december 31 , 2016 and 2015 , respectively . the decrease of $ 623 is primarily attributable to decreases in headcount and the elimination of the 2016 bonuses as a result of our strategic restructuring and ongoing efforts to conserve cash . research facility expenses also decreased by $ 586 from $ 2,421 during the year ended december 31 , 2015 to $ 1,835 for the year ended december 31 , 2016 , primarily as a result of the company 's move to its new woburn , massachusetts facility . story_separator_special_tag restricted cash consists of $ 307 held in connection with the lease agreement for our woburn , massachusetts facility and $ 125 held in connection with our corporate credit card program . 35 investments are made in accordance with our corporate investment policy , as approved by our board of directors . the primary objective of this policy is to preserve principal and investments are limited to high quality corporate debt , u.s. treasury bills and notes , money market funds , bank debt obligations , municipal debt obligations and asset-backed securities . the policy establishes maturity limits , concentration limits , and liquidity requirements . as of december 31 , 2016 , we were in compliance with this policy . we anticipate that our current cash resources will be sufficient to fund operations and meet our obligations , including our restructuring obligations , when due , into the fourth quarter of 2017. this forecast of cash resources is forward-looking information that involves risks and uncertainties , and the actual amount of expenses could vary materially and adversely as a result of a number of factors . we have adopted the new guidance of asu 2014-15 , presentation of financial statements-going concern ( subtopic 205-40 ) in order to determine whether there is substantial doubt about the company 's ability to continue as a going concern for one year after the date its financial statements are issued . the company 's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through , among other sources , public or private equity financing , secured or unsecured debt financing , equity or debt bridge financing , additional government research grants or collaborative arrangements with third parties , as to which no assurances can be given . we do not know whether additional financing will be available on terms favorable or acceptable to the company when needed , if at all . if adequate additional funds are not available when required , or if we are unsuccessful in entering collaborative arrangements for further research , we may be forced to curtail our research efforts , explore strategic alternatives and or wind down our operations and pursue options for liquidating our remaining assets , including intellectual property and equipment . based on our cash forecast , we have determined that the company 's present capital resources are not sufficient to fund our planned operations for a twelve month period , and therefore , raise substantial doubt about its ability to continue as a going concern . although we have $ 20,000 of availability under our equity facility with aspire , market conditions likely will limit the extent to which the company can draw on this facility . we continue to face significant challenges and uncertainties and , as a result , our available capital resources may be consumed more rapidly than currently expected due to ( a ) changes we may make to the business that affect ongoing operating expenses ; ( b ) changes we may make to our business strategy ; ( c ) changes in our research and development spending plans ; and ( d ) other items affecting our forecasted level of expenditures and use of cash resources . our present capital resources will not be sufficient to fund our planned operations for a twelve month period , and therefore , raise substantial doubt about our ability to continue as a going concern . during 2016 , we completed a strategic restructuring of our operations to focus on the yield10 bioscience business . we reduce staffing levels to twenty full-time employees and incurred restructuring costs for contract termination and employee post-termination benefits of approximately $ 3,525 which are primarily reflected in discontinued operations within the company 's statement of operations . at december 31 , 2016 , $ 2,048 of these restructuring charges remain outstanding and are required to be paid out through may 2018. we currently anticipate that we will use approximately $ 7,500 - $ 8,000 of cash during 2017 , including anticipated payments for restructuring costs . this estimated cash usage for operations is significantly less than cash used for operations of $ 14,700 and $ 21,863 during the years ended december 31 , 2016 and 2015 , respectively , and the reduction is primarily the result of our restructuring efforts . on october 7 , 2015 , we entered into a common stock purchase agreement with aspire under which aspire is committed to purchase , at our direction , up to an aggregate of $ 20,000 of shares of our common stock over a 30 month period that will end on may 8 , 2018. common stock may be sold from time to time at the company 's option under pricing formulas based on prevailing market prices around the time of each sale . the extent to which we utilize the facility with aspire as a source of funding will depend on a number of factors , including the prevailing market price of our common stock , the volume of trading in our common stock and the extent to which we are able to secure funds from other sources . the purchase agreement contains limitations on the number of shares that we may issue to aspire . additionally , we and aspire may not effect any sales of shares of our common stock under the purchase agreement during the continuance of an event of default or on any trading day that the closing sale price of our common stock is less than $ 0.50 per share . at december 31 , 2016 , the market price for the company 's common stock was below $ 0.50 and the full $ 20,000 remained available under the purchase agreement with aspire . on december 30 , 2016 , the market price for our common stock closed at $ 0.35 per share . we will need additional capital to

